Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (7), 669-74

Hyperekplexia: A Treatable Neurogenetic Disease


Hyperekplexia: A Treatable Neurogenetic Disease

Lan Zhou et al. Brain Dev.


Hyperekplexia is primarily an autosomal dominant disease characterized by exaggerated startle reflex and neonatal hypertonia. It can be associated with, if untreated, sudden infant death from apnea or aspiration pneumonia and serious injuries and loss of ambulation from frequent falls. Different mutations in the alpha1 subunit of inhibitory glycine receptor (GLRA1) gene have been identified in many affected families. The most common mutation is Arg271 reported in at least 12 independent families. These mutations uncouple the ligand binding and chloride channel function of inhibitory glycine receptor and result in increased excitability in pontomedullary reticular neurons and abnormal spinal reciprocal inhibition. Three mouse models from spontaneous mutations in GLRA1 and beta subunit of inhibitory glycine receptor (GLRB) genes and two transgenic mouse models are valuable for the study of the pathophysiology and the genotype-phenotype correlation of the disease. The disease caused by mutation in GLRB in mice supports the notion that human hyperekplexia with no detectable mutations in GLRA1 may harbor mutations in GLRB. Clonazepam, a gamma aminobutyric acid (GABA) receptor agonist, is highly effective and is the drug of choice. It enhances the GABA-gated chloride channel function and presumably compensates for the defective glycine-gated chloride channel in hyperekplexia. Recognition of the disease will lead to appropriate treatment and genetic counseling.

Similar articles

  • GLRB is the third major gene of effect in hyperekplexia.
    Chung SK, Bode A, Cushion TD, Thomas RH, Hunt C, Wood SE, Pickrell WO, Drew CJ, Yamashita S, Shiang R, Leiz S, Longardt AC, Raile V, Weschke B, Puri RD, Verma IC, Harvey RJ, Ratnasinghe DD, Parker M, Rittey C, Masri A, Lingappa L, Howell OW, Vanbellinghen JF, Mullins JG, Lynch JW, Rees MI. Chung SK, et al. Hum Mol Genet. 2013 Mar 1;22(5):927-40. doi: 10.1093/hmg/dds498. Epub 2012 Nov 25. Hum Mol Genet. 2013. PMID: 23184146
  • [Hyperekplexia -- a treatable neuropediatric disease].
    Freilinger M, Jalowetz S, Reiter E, Schubert MT, Seidl R. Freilinger M, et al. Klin Padiatr. 2005 Jul-Aug;217(4):220-1. doi: 10.1055/s-2004-820286. Klin Padiatr. 2005. PMID: 16032547 German.
  • Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia.
    Chung SK, Vanbellinghen JF, Mullins JG, Robinson A, Hantke J, Hammond CL, Gilbert DF, Freilinger M, Ryan M, Kruer MC, Masri A, Gurses C, Ferrie C, Harvey K, Shiang R, Christodoulou J, Andermann F, Andermann E, Thomas RH, Harvey RJ, Lynch JW, Rees MI. Chung SK, et al. J Neurosci. 2010 Jul 14;30(28):9612-20. doi: 10.1523/JNEUROSCI.1763-10.2010. J Neurosci. 2010. PMID: 20631190 Free PMC article.
  • Hyperekplexia: abnormal startle response due to glycine receptor mutations.
    Andrew M, Owen MJ. Andrew M, et al. Br J Psychiatry. 1997 Feb;170:106-8. doi: 10.1192/bjp.170.2.106. Br J Psychiatry. 1997. PMID: 9093496 Review.
  • The genetics of hyperekplexia: more than startle!
    Harvey RJ, Topf M, Harvey K, Rees MI. Harvey RJ, et al. Trends Genet. 2008 Sep;24(9):439-47. doi: 10.1016/j.tig.2008.06.005. Epub 2008 Aug 15. Trends Genet. 2008. PMID: 18707791 Review.
See all similar articles

Cited by 19 articles

See all "Cited by" articles

LinkOut - more resources